11 news items
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
Committed to 100-250 Basis Points Core Operating
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK
22 Apr 24
biopharmaceutical company headquartered in Japan, we are guided by our commitment
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
Business Unit, Takeda. "Our development of a subcutaneous option demonstrates Takeda's commitment to meeting the very real needs of those living
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
lives and work. As medical teams and individuals in this community, we are committed to promoting the spirit of unlimited support with the goal
8r2e2 a1jyt5d8ffwplb6k4mokxusu1
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
lhl6urnoj
TAK
26 Mar 24
with new possibilities and continue our 70-plus year commitment to the rare disease community."The approval is supported by the totality
ynvf wsy15pcolxsk
TAK
13 Mar 24
-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees
l73mttndfvp8ce6dyky6tu3vxedc0v co2x9tny2c8s2b8yvswp
TAK
26 Feb 24
Vaccine, QDENGA, in multi-dose vials," affirmed Ms. Mahima Datla, managing director at Biological E. Limited. "Takeda's commitment to patient-focused, value
dhddqpbi83n6soo5su7zo8780u 6umxk
TAK
26 Feb 24
headquartered in Japan, committed to discovering and delivering life
z4f6bn0so6cm4kd7dczcaazqer5pxp7du66hwi9g7ju1r35lkyaily8m
TAK
13 Feb 24
&D-driven biopharmaceutical leader headquartered in Japan, committed
- Prev
- 1
- Next